Outcomes of Patients With Large B‐Cell Lymphomas and Progressive Disease Following CD19‐Specific CAR T‐Cell Therapy

American Journal of Hematology - United States
doi 10.1002/ajh.25505
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Cd19-Directed Car T Cell Therapy (Ctl019) for Relapsed/Refractory Diffuse Large B-Cell and Follicular Lymphomas: Four Year Outcomes

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Rapid Relapse of Large B‐Cell Lymphoma After CD19 Directed CAR‐T‐Cell Therapy Due to CD‐19 Antigen Loss

American Journal of Hematology
Hematology
2019English

Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Toxicities of CD19 CAR-T Cell Immunotherapy

American Journal of Hematology
Hematology
2019English

Cd19/Cd20-Redirected Bispecific Car T Cell Treatment in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Clinical Outcomes From Venetoclax Based Therapy in Patients With Relapsed/Refractory B-Cell Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

MSKCC Early Experience Using Radiotherapy as a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma Before Cd19 Car T Therapy

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Combining CD19 Redirection and Alloanergization to Generate Tumor-Specific Human T Cells for Allogeneic Cell Therapy of B-Cell Malignancies

Cancer Research
Cancer ResearchOncology
2010English

Role of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

Memo - Magazine of European Medical Oncology
OncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy